Evidence map›Paper›PMID 31747308›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2020

Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.

Andrew Rasky, David M Habiel, Susan Morris, Matthew Schaller, Bethany B Moore, Sem Phan, Steven L Kunkel, Martin Phillips, Cory Hogaboam, Nicholas W Lukacs

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Human Lung Mast Cells: Therapeutic Implications in Asthma.International journal of molecular sciences · 2022
    Review
  5. Article
  6. 'Youthful' phenotype of c-KitCellular and molecular life sciences : CMLS · 2022
    Article
  7. KIT as a master regulator of the mast cell lineage.The Journal of allergy and clinical immunology · 2022
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Andrew RaskyDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
David M HabielCedars-Sinai Medical Center, Los Angeles, California.
Susan MorrisDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Matthew SchallerDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3338-0655
Bethany B MooreDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Sem PhanDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Steven L KunkelDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Martin PhillipsOpsidio, LLC, Bryn Mawr, Pennsylvania.
Cory HogaboamCedars-Sinai Medical Center, Los Angeles, California.
Nicholas W LukacsDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-2403-6481
University of Michigan · USBryn Mawr College · USCedars-Sinai Medical Center · US

Funding

Immunobiology of Lung Injury and FibrosisR35HL144481 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOORE, BETHANY B. · 2019 to 2024
$5.2M
Innate DNA sensing in rapidly progressing IPFR01HL123899 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI HOGABOAM, CORY M · 2015 to 2018
$2.0M
NHLBI NIH HHS R01 HL123899NHLBI NIH HHS R35 HL144481
6 · The paper itself

Abstract

Stem cell factor (SCF) and its receptor c-kit have been implicated in inflammation, tissue remodeling, and fibrosis. Ingenuity Integrated Pathway Analysis of gene expression array data sets showed an upregulation of SCF transcripts in idiopathic pulmonary fibrosis (IPF) lung biopsies compared with tissue from nonfibrotic lungs that are further increased in rapid progressive disease. SCF248, a cleavable isoform of SCF, was abundantly and preferentially expressed in human lung fibroblasts and fibrotic mouse lungs relative to the SCF220 isoform. In fibroblast-mast cell coculture studies, blockade of SCF248 using a novel isoform-specific anti-SCF248 monoclonal antibody (anti-SCF248), attenuated the expression of

Indexed as

AnimalsBleomycinCell CountCells, CulturedCoculture TechniquesFemaleFibroblastsFibrosisHumansIdiopathic Pulmonary FibrosisLungMast CellsMiceMice, Inbred C57BLProtein IsoformsSignal TransductionBleomycinProtein IsoformsStem Cell Factorcytokinesfibrosismast cells

Identifiers

PMID31747308
PMCPMC6985874
OpenAlexW2990351198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.